| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 21 | 2019 | 481 | 2.980 |
Why?
|
| Genetic Testing | 37 | 2024 | 1692 | 2.290 |
Why?
|
| Cancer Survivors | 13 | 2024 | 746 | 1.940 |
Why?
|
| Genetic Counseling | 20 | 2024 | 417 | 1.710 |
Why?
|
| Mastectomy | 14 | 2023 | 1554 | 1.450 |
Why?
|
| Family | 13 | 2021 | 782 | 1.380 |
Why?
|
| Breast Neoplasms | 32 | 2023 | 16244 | 1.190 |
Why?
|
| Neoplasms | 29 | 2024 | 15949 | 1.150 |
Why?
|
| Patient Compliance | 4 | 2023 | 678 | 1.150 |
Why?
|
| Surveys and Questionnaires | 34 | 2024 | 5923 | 1.150 |
Why?
|
| Perception | 5 | 2020 | 348 | 1.090 |
Why?
|
| Early Detection of Cancer | 7 | 2021 | 1344 | 1.060 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2021 | 232 | 1.040 |
Why?
|
| Colorectal Neoplasms | 11 | 2022 | 3707 | 1.030 |
Why?
|
| Communication | 8 | 2021 | 841 | 1.010 |
Why?
|
| Family Relations | 3 | 2017 | 87 | 0.830 |
Why?
|
| Patient Preference | 5 | 2021 | 230 | 0.820 |
Why?
|
| Quality of Life | 20 | 2024 | 4810 | 0.740 |
Why?
|
| Ovarian Neoplasms | 13 | 2022 | 4809 | 0.730 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2021 | 24 | 0.710 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2021 | 1225 | 0.690 |
Why?
|
| Watchful Waiting | 1 | 2022 | 293 | 0.680 |
Why?
|
| Survivors | 7 | 2023 | 1021 | 0.680 |
Why?
|
| Feasibility Studies | 7 | 2023 | 2360 | 0.650 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2024 | 5777 | 0.650 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2024 | 601 | 0.640 |
Why?
|
| Genes, BRCA2 | 8 | 2021 | 322 | 0.620 |
Why?
|
| Decision Making | 8 | 2020 | 1249 | 0.590 |
Why?
|
| Health Education | 3 | 2020 | 302 | 0.580 |
Why?
|
| Deglutition Disorders | 1 | 2022 | 488 | 0.580 |
Why?
|
| Family Health | 5 | 2014 | 347 | 0.570 |
Why?
|
| Female | 91 | 2024 | 148885 | 0.570 |
Why?
|
| Genes, BRCA1 | 7 | 2016 | 397 | 0.560 |
Why?
|
| Patient Reported Outcome Measures | 9 | 2024 | 879 | 0.550 |
Why?
|
| Health Personnel | 6 | 2021 | 650 | 0.550 |
Why?
|
| Humans | 120 | 2024 | 270713 | 0.550 |
Why?
|
| Head and Neck Neoplasms | 4 | 2023 | 4148 | 0.540 |
Why?
|
| Internet | 3 | 2017 | 687 | 0.530 |
Why?
|
| Adult | 60 | 2024 | 82041 | 0.520 |
Why?
|
| Prophylactic Mastectomy | 4 | 2021 | 38 | 0.510 |
Why?
|
| Telemedicine | 1 | 2021 | 556 | 0.480 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 289 | 0.480 |
Why?
|
| Remote Sensing Technology | 1 | 2013 | 12 | 0.460 |
Why?
|
| Medical Oncology | 2 | 2021 | 1464 | 0.440 |
Why?
|
| Sunburn | 3 | 2021 | 35 | 0.440 |
Why?
|
| Dehydration | 1 | 2013 | 92 | 0.440 |
Why?
|
| Computers, Handheld | 1 | 2013 | 60 | 0.430 |
Why?
|
| Middle Aged | 54 | 2024 | 90533 | 0.430 |
Why?
|
| Sexual and Gender Minorities | 2 | 2024 | 77 | 0.420 |
Why?
|
| Heterozygote | 6 | 2022 | 1057 | 0.410 |
Why?
|
| Attitude to Health | 8 | 2019 | 434 | 0.410 |
Why?
|
| Young Adult | 26 | 2024 | 22243 | 0.400 |
Why?
|
| Pilot Projects | 3 | 2023 | 2856 | 0.380 |
Why?
|
| Information Dissemination | 2 | 2011 | 268 | 0.370 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 112 | 0.370 |
Why?
|
| Siblings | 2 | 2009 | 319 | 0.360 |
Why?
|
| Risk Assessment | 8 | 2017 | 6766 | 0.350 |
Why?
|
| Life Style | 3 | 2021 | 617 | 0.350 |
Why?
|
| Aged | 38 | 2024 | 73613 | 0.350 |
Why?
|
| Li-Fraumeni Syndrome | 2 | 2008 | 166 | 0.340 |
Why?
|
| Risk Management | 2 | 2021 | 111 | 0.330 |
Why?
|
| Patient Satisfaction | 9 | 2024 | 924 | 0.330 |
Why?
|
| Male | 48 | 2024 | 128479 | 0.320 |
Why?
|
| Brachytherapy | 4 | 2023 | 1005 | 0.320 |
Why?
|
| Adolescent | 24 | 2024 | 32689 | 0.310 |
Why?
|
| Genital Neoplasms, Female | 2 | 2013 | 794 | 0.310 |
Why?
|
| Uterine Neoplasms | 2 | 2023 | 578 | 0.310 |
Why?
|
| BRCA2 Protein | 4 | 2021 | 380 | 0.300 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 31116 | 0.300 |
Why?
|
| Technology | 2 | 2022 | 100 | 0.300 |
Why?
|
| Health Behavior | 5 | 2024 | 599 | 0.290 |
Why?
|
| Stress, Psychological | 5 | 2024 | 1038 | 0.280 |
Why?
|
| Jews | 1 | 2007 | 57 | 0.280 |
Why?
|
| Mental Health Services | 3 | 2024 | 258 | 0.280 |
Why?
|
| Mass Screening | 6 | 2019 | 1547 | 0.280 |
Why?
|
| BRCA1 Protein | 4 | 2021 | 528 | 0.280 |
Why?
|
| Adaptation, Psychological | 7 | 2022 | 783 | 0.270 |
Why?
|
| Social Media | 2 | 2021 | 207 | 0.270 |
Why?
|
| Endometrial Neoplasms | 3 | 2022 | 1386 | 0.260 |
Why?
|
| Terminal Care | 2 | 2021 | 467 | 0.260 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 494 | 0.260 |
Why?
|
| Point Mutation | 1 | 2008 | 785 | 0.250 |
Why?
|
| Patient Participation | 4 | 2016 | 454 | 0.250 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2024 | 742 | 0.250 |
Why?
|
| Focus Groups | 4 | 2014 | 282 | 0.230 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 4494 | 0.210 |
Why?
|
| Mutation | 14 | 2021 | 15917 | 0.210 |
Why?
|
| Florida | 1 | 2022 | 114 | 0.210 |
Why?
|
| Precision Medicine | 3 | 2016 | 1216 | 0.210 |
Why?
|
| Social Networking | 1 | 2022 | 27 | 0.200 |
Why?
|
| Ovariectomy | 4 | 2021 | 370 | 0.200 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2023 | 136 | 0.200 |
Why?
|
| Vital Signs | 1 | 2022 | 24 | 0.200 |
Why?
|
| Psychometrics | 2 | 2024 | 975 | 0.200 |
Why?
|
| Electronics | 1 | 2022 | 62 | 0.200 |
Why?
|
| Sunscreening Agents | 3 | 2021 | 35 | 0.190 |
Why?
|
| Decision Support Techniques | 2 | 2006 | 603 | 0.190 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2021 | 26 | 0.190 |
Why?
|
| Salpingo-oophorectomy | 1 | 2021 | 51 | 0.190 |
Why?
|
| Confidentiality | 3 | 2014 | 117 | 0.190 |
Why?
|
| Environmental Health | 1 | 2001 | 14 | 0.190 |
Why?
|
| Colonoscopy | 2 | 2017 | 524 | 0.190 |
Why?
|
| Risk Factors | 15 | 2023 | 17861 | 0.190 |
Why?
|
| Registries | 3 | 2024 | 2210 | 0.190 |
Why?
|
| Chronic Disease | 5 | 2023 | 1824 | 0.180 |
Why?
|
| SEER Program | 2 | 2024 | 1052 | 0.180 |
Why?
|
| Biometry | 1 | 2023 | 251 | 0.180 |
Why?
|
| Surgical Oncology | 2 | 2020 | 212 | 0.180 |
Why?
|
| Radiotherapy | 3 | 2023 | 1858 | 0.180 |
Why?
|
| Oncology Nursing | 1 | 2001 | 54 | 0.180 |
Why?
|
| Public Opinion | 1 | 2001 | 74 | 0.180 |
Why?
|
| Patient Education as Topic | 5 | 2017 | 747 | 0.180 |
Why?
|
| Thyroid Neoplasms | 2 | 2024 | 1908 | 0.180 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 1956 | 0.180 |
Why?
|
| Socioeconomic Factors | 5 | 2023 | 1250 | 0.170 |
Why?
|
| Self-Help Groups | 1 | 2020 | 35 | 0.170 |
Why?
|
| Referral and Consultation | 3 | 2021 | 930 | 0.170 |
Why?
|
| Texas | 7 | 2024 | 6446 | 0.170 |
Why?
|
| Hospice Care | 1 | 2021 | 163 | 0.160 |
Why?
|
| Health Communication | 1 | 2019 | 35 | 0.160 |
Why?
|
| Mastectomy, Segmental | 5 | 2023 | 1050 | 0.160 |
Why?
|
| Risk Reduction Behavior | 2 | 2010 | 210 | 0.160 |
Why?
|
| Culture | 1 | 2019 | 104 | 0.160 |
Why?
|
| Survivorship | 3 | 2024 | 116 | 0.150 |
Why?
|
| Disclosure | 2 | 2013 | 180 | 0.150 |
Why?
|
| Program Development | 1 | 2019 | 257 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2023 | 551 | 0.150 |
Why?
|
| Health Literacy | 1 | 2019 | 118 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2020 | 335 | 0.150 |
Why?
|
| Qualitative Research | 3 | 2019 | 638 | 0.150 |
Why?
|
| Oncogenes | 1 | 2001 | 697 | 0.140 |
Why?
|
| Primary Prevention | 2 | 2010 | 233 | 0.140 |
Why?
|
| Cultural Characteristics | 1 | 2017 | 64 | 0.140 |
Why?
|
| Energy Intake | 1 | 2019 | 517 | 0.140 |
Why?
|
| Skin Neoplasms | 3 | 2021 | 4899 | 0.140 |
Why?
|
| Mammography | 1 | 2022 | 1055 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 1257 | 0.130 |
Why?
|
| Information Seeking Behavior | 1 | 2016 | 20 | 0.130 |
Why?
|
| Melanoma | 3 | 2021 | 5599 | 0.130 |
Why?
|
| Physician's Role | 1 | 2018 | 228 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 907 | 0.130 |
Why?
|
| Paraganglioma | 1 | 2018 | 200 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2018 | 293 | 0.130 |
Why?
|
| Risk | 3 | 2015 | 1930 | 0.130 |
Why?
|
| Pedigree | 3 | 2016 | 2040 | 0.120 |
Why?
|
| Mammaplasty | 1 | 2022 | 714 | 0.120 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2005 | 33 | 0.120 |
Why?
|
| Pheochromocytoma | 1 | 2018 | 310 | 0.120 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2023 | 1162 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 465 | 0.120 |
Why?
|
| Interviews as Topic | 4 | 2019 | 518 | 0.120 |
Why?
|
| Patient Selection | 3 | 2014 | 2029 | 0.110 |
Why?
|
| Social Class | 3 | 2023 | 317 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 2658 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 882 | 0.110 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 379 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2018 | 527 | 0.110 |
Why?
|
| Social Support | 5 | 2020 | 585 | 0.100 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 602 | 0.100 |
Why?
|
| Infertility, Female | 1 | 2014 | 209 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 6193 | 0.100 |
Why?
|
| Sarcoma | 1 | 2023 | 1851 | 0.100 |
Why?
|
| Smith-Magenis Syndrome | 1 | 2013 | 123 | 0.100 |
Why?
|
| Demography | 1 | 2013 | 432 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2021 | 13419 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 626 | 0.100 |
Why?
|
| Fallopian Tubes | 1 | 2010 | 129 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2017 | 2227 | 0.090 |
Why?
|
| Death | 2 | 2021 | 129 | 0.080 |
Why?
|
| Mental Health | 2 | 2023 | 408 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2014 | 696 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 657 | 0.080 |
Why?
|
| Gynecology | 1 | 2010 | 233 | 0.080 |
Why?
|
| Obstetrics | 1 | 2010 | 235 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2023 | 2272 | 0.070 |
Why?
|
| New Jersey | 1 | 2007 | 34 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 15275 | 0.070 |
Why?
|
| Health Surveys | 3 | 2015 | 395 | 0.070 |
Why?
|
| Salpingostomy | 1 | 2006 | 8 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2023 | 6233 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2017 | 2315 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1076 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 850 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 39959 | 0.070 |
Why?
|
| Genetic Privacy | 1 | 2007 | 44 | 0.070 |
Why?
|
| United States | 6 | 2023 | 15828 | 0.070 |
Why?
|
| Self Efficacy | 1 | 2008 | 297 | 0.070 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 1610 | 0.070 |
Why?
|
| Parents | 1 | 2013 | 1083 | 0.060 |
Why?
|
| Disease Management | 2 | 2022 | 1092 | 0.060 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2006 | 155 | 0.060 |
Why?
|
| Motivation | 2 | 2018 | 515 | 0.060 |
Why?
|
| Spouses | 2 | 2024 | 145 | 0.060 |
Why?
|
| Duty to Recontact | 1 | 2024 | 8 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 2177 | 0.060 |
Why?
|
| Truth Disclosure | 2 | 2013 | 178 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 2339 | 0.060 |
Why?
|
| Professional Role | 1 | 2005 | 75 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2023 | 9463 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2396 | 0.060 |
Why?
|
| Bisexuality | 1 | 2023 | 21 | 0.060 |
Why?
|
| California | 1 | 2024 | 212 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2008 | 1140 | 0.060 |
Why?
|
| Hot Flashes | 1 | 2023 | 35 | 0.060 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 209 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 2051 | 0.060 |
Why?
|
| Persuasive Communication | 1 | 2003 | 17 | 0.050 |
Why?
|
| Gender Identity | 1 | 2023 | 80 | 0.050 |
Why?
|
| Educational Status | 3 | 2014 | 387 | 0.050 |
Why?
|
| Intestinal Polyps | 1 | 2003 | 79 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2004 | 166 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 11 | 0.050 |
Why?
|
| Oncologists | 1 | 2024 | 136 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 7055 | 0.050 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2019 | 206 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 179 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 2658 | 0.050 |
Why?
|
| Minority Groups | 1 | 2004 | 325 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 294 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2022 | 352 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2023 | 314 | 0.050 |
Why?
|
| Nursing Evaluation Research | 1 | 2001 | 11 | 0.050 |
Why?
|
| Education, Nursing | 1 | 2001 | 18 | 0.050 |
Why?
|
| Pregnancy | 4 | 2017 | 7916 | 0.040 |
Why?
|
| Spirometry | 1 | 2020 | 153 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2022 | 202 | 0.040 |
Why?
|
| Child | 5 | 2024 | 30560 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2019 | 49 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 14033 | 0.040 |
Why?
|
| Counseling | 1 | 2022 | 380 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2010 | 1442 | 0.040 |
Why?
|
| Research Design | 2 | 2024 | 1562 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2022 | 506 | 0.040 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 732 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2001 | 481 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 149 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 419 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2020 | 283 | 0.040 |
Why?
|
| Software | 1 | 2005 | 1357 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 482 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 585 | 0.040 |
Why?
|
| Body Image | 1 | 2018 | 125 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 9053 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 238 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 999 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 5258 | 0.030 |
Why?
|
| Counselors | 1 | 2017 | 27 | 0.030 |
Why?
|
| Linear Models | 1 | 2020 | 1093 | 0.030 |
Why?
|
| Folic Acid | 1 | 2019 | 370 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 129 | 0.030 |
Why?
|
| Postmenopause | 1 | 2017 | 374 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 188 | 0.030 |
Why?
|
| Health Planning | 1 | 2015 | 28 | 0.030 |
Why?
|
| Grounded Theory | 1 | 2014 | 10 | 0.030 |
Why?
|
| Incidence | 2 | 2016 | 5825 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 245 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 1307 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 4007 | 0.030 |
Why?
|
| Probability | 1 | 2016 | 886 | 0.030 |
Why?
|
| Marital Status | 1 | 2014 | 89 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1287 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 107 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 926 | 0.030 |
Why?
|
| Preimplantation Diagnosis | 1 | 2014 | 37 | 0.030 |
Why?
|
| Emotions | 1 | 2017 | 558 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1608 | 0.030 |
Why?
|
| Telecommunications | 1 | 2013 | 27 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 3656 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 988 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 628 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 812 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10268 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 631 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 536 | 0.030 |
Why?
|
| Anxiety | 2 | 1997 | 1245 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 1903 | 0.030 |
Why?
|
| Pain | 1 | 2021 | 1701 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 314 | 0.030 |
Why?
|
| Chromosome Duplication | 1 | 2013 | 154 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 4317 | 0.030 |
Why?
|
| Exercise | 1 | 2019 | 1221 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 2013 | 420 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2016 | 2033 | 0.020 |
Why?
|
| Depression | 2 | 1997 | 1733 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1997 | 1435 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1997 | 1240 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 10404 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 1828 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 4992 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 5099 | 0.020 |
Why?
|
| Prognosis | 2 | 2018 | 22528 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2013 | 1101 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 602 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 1023 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 3906 | 0.020 |
Why?
|
| Parity | 1 | 2006 | 124 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1562 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 599 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 12978 | 0.020 |
Why?
|
| Information Services | 1 | 2006 | 42 | 0.020 |
Why?
|
| Colposcopy | 1 | 2005 | 75 | 0.020 |
Why?
|
| Breast | 1 | 2012 | 1370 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 708 | 0.020 |
Why?
|
| Medical Informatics | 1 | 2006 | 152 | 0.010 |
Why?
|
| Survival Rate | 1 | 2017 | 12530 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 966 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2017 | 33847 | 0.010 |
Why?
|
| Logistic Models | 2 | 2004 | 3429 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2006 | 652 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2003 | 240 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2010 | 1331 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2005 | 636 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 448 | 0.010 |
Why?
|
| Europe | 1 | 2003 | 650 | 0.010 |
Why?
|
| Smoking | 1 | 2009 | 2549 | 0.010 |
Why?
|
| Income | 1 | 1999 | 232 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 10726 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2004 | 2258 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 5441 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 16741 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14638 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 1997 | 1462 | 0.010 |
Why?
|
| DNA Repair | 1 | 1997 | 1906 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1997 | 2085 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1997 | 2618 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 3435 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 3345 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 7920 | 0.000 |
Why?
|